Proven efficacy for reducing subsequent stroke in patients with prior TIA or stroke2,3

fewer strokes vs low-dose aspirin* alone

AGGRENOX reduced the risk of subsequent stroke by 22.1% compared to low-dose aspirin alone over 2 years (P=0.008).2

stroke-free rate

In 2 large clinical trials, ESPS 2 and PRoFESS, 91% of patients on AGGRENOX remained stroke-free for 2 years.2,3

as effective as low-dose aspirin* compared to placebo

AGGRENOX was 2 times as effective as low-dose aspirin alone in reducing the risk of subsequent stroke when compared to placebo.2

AGGRENOX had bleeding rates similar to aspirin but higher than placebo.2

*25 mg twice daily.

European Stroke Prevention Study 2 (ESPS 2): A randomized, double-blind, placebo-controlled, 24-month trial comparing 25 mg low-dose aspirin alone, 200 mg ER-DP, and the 2 agents in combination (AGGRENOX), in 6,602 patients with prior ischemic stroke or TIA. All treatments were given twice daily.2

Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS): A double-blind, 2-by-2 factorial trial in which 20,332 patients were randomized to 25 mg of aspirin plus 200 mg of ER-DP twice daily or to 75 mg of clopidogrel once daily over a mean duration of 2.5 years. Trial failed to meet its primary endpoint, and thus the comparison to clopidogrel was not conclusive.3

TIA=transient ischemic attack; ER-DP=extended-release dipyridamole.